Back to Search
Start Over
The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.
- Source :
- Diabetes Care; Aug2021, Vol. 44 Issue 8, p1805-1815, 11p
- Publication Year :
- 2021
-
Abstract
- <bold>Objective: </bold>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve albuminuria in patients with high cardiorenal risk. We report albuminuria change in the Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) cardiovascular outcome trial, which included populations with lower cardiorenal risk.<bold>Research Design and Methods: </bold>DECLARE-TIMI 58 randomized 17,160 patients with type 2 diabetes, creatinine clearance >60 mL/min, and either atherosclerotic cardiovascular disease (CVD; 40.6%) or risk-factors for CVD (59.4%) to dapagliflozin or placebo. Urinary albumin-to-creatinine ratio (UACR) was tested at baseline, 6 months, 12 months, and yearly thereafter. The change in UACR over time was measured as a continuous and categorical variable (≤15, >15 to <30, ≥30 to ≤300, and >300 mg/g) by treatment arm. The composite cardiorenal outcome was a ≥40% sustained decline in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m2, end-stage kidney disease, and cardiovascular or renal death; specific renal outcome included all except cardiovascular death.<bold>Results: </bold>Baseline UACR was available for 16,843 (98.15%) participants: 9,067 (53.83%) with ≤15 mg/g, 2,577 (15.30%) with >15 to <30 mg/g, 4,030 (23.93%) with 30-300 mg/g, and 1,169 (6.94%) with >300 mg/g. Measured as a continuous variable, UACR improved from baseline to 4.0 years with dapagliflozin, compared with placebo, across all UACR and eGFR categories (all P < 0.0001). Sustained confirmed ≥1 category improvement in UACR was more common in dapagliflozin versus placebo (hazard ratio 1.45 [95% CI 1.35-1.56], P < 0.0001). Cardiorenal outcome was reduced with dapagliflozin for subgroups of UACR ≥30 mg/g (P < 0.0125, Pinteraction = 0.033), and the renal-specific outcome was reduced for all UACR subgroups (P < 0.05, Pinteraction = 0.480).<bold>Conclusions: </bold>In DECLARE-TIMI 58, dapagliflozin demonstrated a favorable effect on UACR and renal-specific outcome across baseline UACR categories, including patients with normal albumin excretion. The results suggest a role for SGLT2i also in the primary prevention of diabetic kidney disease. [ABSTRACT FROM AUTHOR]
- Subjects :
- SODIUM-glucose cotransporter 2 inhibitors
DIABETIC nephropathies
DAPAGLIFLOZIN
CHRONIC kidney failure
ALBUMINURIA
BENZENE
GLOMERULAR filtration rate
RESEARCH
GLYCOSIDES
MEDICAL cooperation
TYPE 2 diabetes
COMPARATIVE studies
RANDOMIZED controlled trials
STATISTICAL sampling
DISEASE complications
Subjects
Details
- Language :
- English
- ISSN :
- 01495992
- Volume :
- 44
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Diabetes Care
- Publication Type :
- Academic Journal
- Accession number :
- 152055354
- Full Text :
- https://doi.org/10.2337/dc21-0076